NRXP Stock Overview
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
NRx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.17 |
| 52 Week High | US$3.54 |
| 52 Week Low | US$0.49 |
| Beta | 0.99 |
| 1 Month Change | 5.41% |
| 3 Month Change | 31.06% |
| 1 Year Change | -60.20% |
| 3 Year Change | n/a |
| 5 Year Change | -87.99% |
| Change since IPO | -87.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRXP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.6% | -1.6% | 1.7% |
| 1Y | -60.2% | 3.2% | -12.5% |
Return vs Industry: NRXP underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: NRXP underperformed the US Market which returned -13.6% over the past year.
Price Volatility
| NRXP volatility | |
|---|---|
| NRXP Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NRXP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: NRXP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Steve Willard | https://www.nrxpharma.com |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. Fundamentals Summary
| NRXP fundamental statistics | |
|---|---|
| Market Cap | US$79.14m |
| Earnings (TTM) | -US$315.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs NRXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRXP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$315.74m |
| Earnings | -US$315.74m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NRXP perform over the long term?
See historical performance and comparison